BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:JAB-8263 readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of JAB-8263\, from ClinicalTrials.gov estima
 tes.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07684157-2560@assetmemo.bio
DTSTAMP:20261121T005718Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:JAB-8263: Phase 2 readout est. (NCT07684157)
DESCRIPTION:JAB-8263\, phase 2\, Rheumatoid Arthritis.\nStudy: A Phase IIa 
 Study of JAB-8263 in Patients With Active Rheumatoid Arthritis\nEstimated 
 primary completion: 30 June 2027. This is a ClinicalTrials.gov estimate\, 
 not a confirmed readout date\, and it can move.\nDrug page: https://assetm
 emo.bio/drug/jab-8263#upcoming-events\nRegistry record: https://clinicaltr
 ials.gov/study/NCT07684157
URL:https://assetmemo.bio/drug/jab-8263#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04686682-2560@assetmemo.bio
DTSTAMP:20261121T005718Z
DTSTART;VALUE=DATE:20280131
DTEND;VALUE=DATE:20280201
SUMMARY:JAB-8263: Phase 1/2 readout est. (NCT04686682)
DESCRIPTION:JAB-8263\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy: A Fi
 rst-in-Human\, JAB-8263 in Adult Patients With Advanced Tumors\nEstimated 
 primary completion: January 2028. This is a ClinicalTrials.gov estimate\, 
 not a confirmed readout date\, and it can move.\nDrug page: https://assetm
 emo.bio/drug/jab-8263#upcoming-events\nRegistry record: https://clinicaltr
 ials.gov/study/NCT04686682
URL:https://assetmemo.bio/drug/jab-8263#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
